{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:10:56Z","timestamp":1782141056403,"version":"3.54.5"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","award":["G-17-0018231"],"award-info":[{"award-number":["G-17-0018231"]}],"id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Diabetes Canada"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00018-018-2857-1","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T03:52:27Z","timestamp":1529639547000},"page":"3193-3213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Histones and heart failure in diabetes"],"prefix":"10.1007","volume":"75","author":[{"given":"Veera Ganesh","family":"Yerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0497-645X","authenticated-orcid":false,"given":"Andrew","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,22]]},"reference":[{"key":"2857_CR1","doi-asserted-by":"publisher","first-page":"g7607","DOI":"10.1136\/bmj.g7607","volume":"350","author":"KK Tsilidis","year":"2015","unstructured":"Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP (2015) Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 350:g7607","journal-title":"BMJ"},{"key":"2857_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3233\/JAD-160114","volume":"53","author":"W Li","year":"2016","unstructured":"Li W, Huang E (2016) An update on type 2 diabetes mellitus as a risk factor for dementia. J Alzheimers Dis 53:393\u2013402","journal-title":"J Alzheimers Dis"},{"key":"2857_CR3","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00264-016-3146-y","volume":"40","author":"J Wang","year":"2016","unstructured":"Wang J, You W, Jing Z, Wang R, Fu Z, Wang Y (2016) Increased risk of vertebral fracture in patients with diabetes: a meta-analysis of cohort studies. Int Orthop 40:1299\u20131307","journal-title":"Int Orthop"},{"key":"2857_CR4","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2337\/diacare.26.8.2433","volume":"26","author":"DS Bell","year":"2003","unstructured":"Bell DS (2003) Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26:2433\u20132441","journal-title":"Diabetes Care"},{"key":"2857_CR5","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1161\/CIRCRESAHA.116.306819","volume":"118","author":"ST Keating","year":"2016","unstructured":"Keating ST, Plutzky J, El-Osta A (2016) Epigenetic changes in diabetes and cardiovascular risk. Circ Res 118:1706\u20131722","journal-title":"Circ Res"},{"key":"2857_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00125-017-4490-1","volume":"61","author":"ST Keating","year":"2018","unstructured":"Keating ST, van Diepen JA, Riksen NP, El-Osta A (2018) Epigenetics in diabetic nephropathy, immunity and metabolism. Diabetologia 61:6\u201320","journal-title":"Diabetologia"},{"key":"2857_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrneph.2014.116","volume":"10","author":"M Kato","year":"2014","unstructured":"Kato M, Natarajan R (2014) Diabetic nephropathy\u2013emerging epigenetic mechanisms. Nat Rev Nephrol 10:517\u2013530","journal-title":"Nat Rev Nephrol"},{"key":"2857_CR8","doi-asserted-by":"publisher","first-page":"635284","DOI":"10.1155\/2013\/635284","volume":"2013","author":"RA Kowluru","year":"2013","unstructured":"Kowluru RA, Santos JM, Mishra M (2013) Epigenetic modifications and diabetic retinopathy. Biomed Res Int 2013:635284","journal-title":"Biomed Res Int"},{"key":"2857_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11892-015-0677-3","volume":"15","author":"J Pasquier","year":"2015","unstructured":"Pasquier J, Hoarau-Vechot J, Fakhro K, Rafii A, Abi Khalil C (2015) Epigenetics and cardiovascular disease in diabetes. Curr Diab Rep 15:108","journal-title":"Curr Diab Rep"},{"key":"2857_CR10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1161\/CIRCRESAHA.116.303630","volume":"116","author":"TG Gillette","year":"2015","unstructured":"Gillette TG, Hill JA (2015) Readers, writers, and erasers: chromatin as the whiteboard of heart disease. Circ Res 116:1245\u20131253","journal-title":"Circ Res"},{"key":"2857_CR11","unstructured":"International Diabetes Federation (2017) IDF diabetes atlas, 8th edn. \n                    https:\/\/www.idf.org\/e-library\/epidemiology-research\/diabetes-atlas.html\n                    \n                  . Accessed 24 Jan 2018"},{"key":"2857_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","volume":"34","author":"WB Kannel","year":"1974","unstructured":"Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34:29\u201334","journal-title":"Am J Cardiol"},{"key":"2857_CR13","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","volume":"27","author":"GA Nichols","year":"2004","unstructured":"Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879\u20131884","journal-title":"Diabetes Care"},{"key":"2857_CR14","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S2213-8587(15)00292-2","volume":"3","author":"A Rosengren","year":"2015","unstructured":"Rosengren A et al (2015) Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. Lancet Diabetes Endocrinol 3:876\u2013885","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2857_CR15","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2337\/dc17-0697","volume":"40","author":"M Dauriz","year":"2017","unstructured":"Dauriz M, Mantovani A, Bonapace S, Verlato G, Zoppini G, Bonora E, Targher G (2017) Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis. Diabetes Care 40:1597\u20131605","journal-title":"Diabetes Care"},{"key":"2857_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1089\/dia.2016.0132","volume":"18","author":"J Zhu","year":"2016","unstructured":"Zhu J, Kahn P, Knudsen J, Mehta SN, Gabbay RA (2016) Predictive model for estimating the cost of incident diabetes complications. Diabetes Technol Ther 18:625\u2013634","journal-title":"Diabetes Technol Ther"},{"key":"2857_CR17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay SM, Roger VL, Redfield MM (2017) Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 14:591\u2013602","journal-title":"Nat Rev Cardiol"},{"key":"2857_CR18","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","volume":"64","author":"RJ Mentz","year":"2014","unstructured":"Mentz RJ et al (2014) Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 64:2281\u20132293","journal-title":"J Am Coll Cardiol"},{"key":"2857_CR19","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/ejhf.600","volume":"18","author":"F Triposkiadis","year":"2016","unstructured":"Triposkiadis F, Giamouzis G, Parissis J, Starling RC, Boudoulas H, Skoularigis J, Butler J, Filippatos G (2016) Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail 18:744\u2013758","journal-title":"Eur J Heart Fail"},{"key":"2857_CR20","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MR MacDonald","year":"2008","unstructured":"MacDonald MR et al (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29:1377\u20131385","journal-title":"Eur Heart J"},{"key":"2857_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","volume":"30","author":"S Rubler","year":"1972","unstructured":"Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595\u2013602","journal-title":"Am J Cardiol"},{"key":"2857_CR22","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.amjmed.2008.03.046","volume":"121","author":"A Aneja","year":"2008","unstructured":"Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME (2008) Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 121:748\u2013757","journal-title":"Am J Med"},{"key":"2857_CR23","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1093\/eurheartj\/ehm361","volume":"28","author":"E Konduracka","year":"2007","unstructured":"Konduracka E, Gackowski A, Rostoff P, Galicka-Latala D, Frasik W, Piwowarska W (2007) Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J 28:2465\u20132471","journal-title":"Eur Heart J"},{"key":"2857_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/01.CIR.59.1.8","volume":"59","author":"WB Kannel","year":"1979","unstructured":"Kannel WB, McGee DL (1979) Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59:8\u201313","journal-title":"Circulation"},{"key":"2857_CR25","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1097\/HJH.0b013e32832d4aee","volume":"27","author":"DC Suh","year":"2009","unstructured":"Suh DC, Kim CM, Choi IS, Plauschinat CA, Barone JA (2009) Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988\u20132004. J Hypertens 27:1908\u20131916","journal-title":"J Hypertens"},{"key":"2857_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nrcardio.2017.211","volume":"15","author":"M Nassif","year":"2018","unstructured":"Nassif M, Kosiborod M (2018) Effect of glucose-lowering therapies on heart failure. Nat Rev Cardiol 15:282\u2013291","journal-title":"Nat Rev Cardiol"},{"key":"2857_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","volume":"71","author":"TH Marwick","year":"2018","unstructured":"Marwick TH, Ritchie R, Shaw JE, Kaye D (2018) Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol 71:339\u2013351","journal-title":"J Am Coll Cardiol"},{"key":"2857_CR28","doi-asserted-by":"publisher","first-page":"546","DOI":"10.5114\/aoms.2014.43748","volume":"10","author":"J Kasznicki","year":"2014","unstructured":"Kasznicki J, Drzewoski J (2014) Heart failure in the diabetic population\u2014pathophysiology, diagnosis and management. Arch Med Sci 10:546\u2013556","journal-title":"Arch Med Sci"},{"key":"2857_CR29","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR (2018) Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res 122:624\u2013638","journal-title":"Circ Res"},{"key":"2857_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/A:1009884820941","volume":"5","author":"WB Kannel","year":"2000","unstructured":"Kannel WB (2000) Incidence and epidemiology of heart failure. Heart Fail Rev 5:167\u2013173","journal-title":"Heart Fail Rev"},{"key":"2857_CR31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/ajh\/hpy004","volume":"31","author":"TE Brinkley","year":"2018","unstructured":"Brinkley TE et al (2018) Long-term effects of an intensive lifestyle intervention on electrocardiographic criteria for left ventricular hypertrophy: the look AHEAD trial. Am J Hypertens 31:541\u2013548","journal-title":"Am J Hypertens"},{"key":"2857_CR32","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW et al (2013) 2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation 128:1810\u20131852","journal-title":"Circulation"},{"key":"2857_CR33","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1161\/CIR.0000000000000435","volume":"134","author":"M Writing Committee","year":"2016","unstructured":"Writing Committee M et al (2016) 2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 134:e282\u2013e293","journal-title":"Circulation"},{"key":"2857_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jjcc.2013.02.017","volume":"62","author":"H Iwano","year":"2013","unstructured":"Iwano H, Little WC (2013) Heart failure: what does ejection fraction have to do with it? J Cardiol 62:1\u20133","journal-title":"J Cardiol"},{"key":"2857_CR35","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2337\/dc07-1868","volume":"31","author":"DT Investigators","year":"2008","unstructured":"DT Investigators et al (2008) Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 31:1007\u20131014","journal-title":"Diabetes Care"},{"key":"2857_CR36","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279\u20131289","journal-title":"Lancet"},{"key":"2857_CR37","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","volume":"385","author":"F Zannad","year":"2015","unstructured":"Zannad F et al (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385:2067\u20132076","journal-title":"Lancet"},{"key":"2857_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232\u2013242","journal-title":"N Engl J Med"},{"key":"2857_CR39","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247\u20132257","journal-title":"N Engl J Med"},{"key":"2857_CR40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311\u2013322","journal-title":"N Engl J Med"},{"key":"2857_CR41","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844","journal-title":"N Engl J Med"},{"key":"2857_CR42","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317\u20131326","journal-title":"N Engl J Med"},{"key":"2857_CR43","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327\u20131335","journal-title":"N Engl J Med"},{"key":"2857_CR44","unstructured":"U.S. Food and Drug Administration. Guidance for Industry. Diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, December 2008. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071627.pdf\n                    \n                  . Accessed 29 Jan 2018"},{"key":"2857_CR45","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"2857_CR46","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657","journal-title":"N Engl J Med"},{"key":"2857_CR47","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"Fitchett D et al (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 37:1526\u20131534","journal-title":"Eur Heart J"},{"key":"2857_CR48","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/S0960-9822(95)00245-4","volume":"5","author":"T Krude","year":"1995","unstructured":"Krude T (1995) Chromatin. Nucleosome assembly during DNA replication. Curr Biol 5:1232\u20131234","journal-title":"Curr Biol"},{"key":"2857_CR49","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.bbagrm.2015.10.004","volume":"1859","author":"AA Kalashnikova","year":"2016","unstructured":"Kalashnikova AA, Rogge RA, Hansen JC (2016) Linker histone H1 and protein-protein interactions. Biochim Biophys Acta 1859:455\u2013461","journal-title":"Biochim Biophys Acta"},{"key":"2857_CR50","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.bbagrm.2015.09.003","volume":"1859","author":"A Izzo","year":"2016","unstructured":"Izzo A, Schneider R (2016) The role of linker histone H1 modifications in the regulation of gene expression and chromatin dynamics. Biochim Biophys Acta 1859:486\u2013495","journal-title":"Biochim Biophys Acta"},{"key":"2857_CR51","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/cr.2011.22","volume":"21","author":"AJ Bannister","year":"2011","unstructured":"Bannister AJ, Kouzarides T (2011) Regulation of chromatin by histone modifications. Cell Res 21:381\u2013395","journal-title":"Cell Res"},{"key":"2857_CR52","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cell.2007.10.039","volume":"131","author":"CD Allis","year":"2007","unstructured":"Allis CD et al (2007) New nomenclature for chromatin-modifying enzymes. Cell 131:633\u2013636","journal-title":"Cell"},{"key":"2857_CR53","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1073\/pnas.1320850111","volume":"111","author":"DP Christensen","year":"2014","unstructured":"Christensen DP et al (2014) Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and beta-cell protection. Proc Natl Acad Sci USA 111:1055\u20131059","journal-title":"Proc Natl Acad Sci USA"},{"key":"2857_CR54","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tig.2015.10.007","volume":"32","author":"M Lawrence","year":"2016","unstructured":"Lawrence M, Daujat S, Schneider R (2016) Lateral thinking: how histone modifications regulate gene expression. Trends Genet 32:42\u201356","journal-title":"Trends Genet"},{"key":"2857_CR55","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","volume":"128","author":"T Kouzarides","year":"2007","unstructured":"Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693\u2013705","journal-title":"Cell"},{"key":"2857_CR56","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.bbagrm.2014.02.013","volume":"1839","author":"SG Swygert","year":"2014","unstructured":"Swygert SG, Peterson CL (2014) Chromatin dynamics: interplay between remodeling enzymes and histone modifications. Biochim Biophys Acta 1839:728\u2013736","journal-title":"Biochim Biophys Acta"},{"key":"2857_CR57","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1128\/MCB.20.9.3058-3068.2000","volume":"20","author":"M Jaskelioff","year":"2000","unstructured":"Jaskelioff M, Gavin IM, Peterson CL, Logie C (2000) SWI-SNF-mediated nucleosome remodeling: role of histone octamer mobility in the persistence of the remodeled state. Mol Cell Biol 20:3058\u20133068","journal-title":"Mol Cell Biol"},{"key":"2857_CR58","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1002\/j.1460-2075.1996.tb00608.x","volume":"15","author":"M Vettese-Dadey","year":"1996","unstructured":"Vettese-Dadey M, Grant PA, Hebbes TR, Crane- Robinson C, Allis CD, Workman JL (1996) Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA in vitro. EMBO J 15:2508\u20132518","journal-title":"EMBO J"},{"key":"2857_CR59","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cell.2011.01.024","volume":"144","author":"M Bulger","year":"2011","unstructured":"Bulger M, Groudine M (2011) Functional and mechanistic diversity of distal transcription enhancers. Cell 144:327\u2013339","journal-title":"Cell"},{"key":"2857_CR60","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.1128\/MCB.00083-07","volume":"27","author":"M Kininis","year":"2007","unstructured":"Kininis M, Chen BS, Diehl AG, Isaacs GD, Zhang T, Siepel AC, Clark AG, Kraus WL (2007) Genomic analyses of transcription factor binding, histone acetylation, and gene expression reveal mechanistically distinct classes of estrogen-regulated promoters. Mol Cell Biol 27:5090\u20135104","journal-title":"Mol Cell Biol"},{"key":"2857_CR61","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tig.2014.03.002","volume":"30","author":"TA Soboleva","year":"2014","unstructured":"Soboleva TA, Nekrasov M, Ryan DP, Tremethick DJ (2014) Histone variants at the transcription start-site. Trends Genet 30:199\u2013209","journal-title":"Trends Genet"},{"key":"2857_CR62","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1097-2765(03)00288-0","volume":"12","author":"A Clements","year":"2003","unstructured":"Clements A, Poux AN, Lo WS, Pillus L, Berger SL, Marmorstein R (2003) Structural basis for histone and phosphohistone binding by the GCN5 histone acetyltransferase. Mol Cell 12:461\u2013473","journal-title":"Mol Cell"},{"key":"2857_CR63","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1126\/science.1062322","volume":"293","author":"WS Lo","year":"2001","unstructured":"Lo WS, Duggan L, Emre NC, Belotserkovskya R, Lane WS, Shiekhattar R, Berger SL (2001) Snf1\u2014a histone kinase that works in concert with the histone acetyltransferase Gcn5 to regulate transcription. Science 293:1142\u20131146","journal-title":"Science"},{"key":"2857_CR64","doi-asserted-by":"publisher","first-page":"7541","DOI":"10.1073\/pnas.1017374108","volume":"108","author":"L Shi","year":"2011","unstructured":"Shi L et al (2011) Histone demethylase JMJD2B coordinates H3K4\/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci USA 108:7541\u20137546","journal-title":"Proc Natl Acad Sci USA"},{"key":"2857_CR65","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1126\/science.1111098","volume":"187","author":"R Holliday","year":"1975","unstructured":"Holliday R, Pugh JE (1975) DNA modification mechanisms and gene activity during development. Science 187:226\u2013232","journal-title":"Science"},{"key":"2857_CR66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000130315","volume":"14","author":"AD Riggs","year":"1975","unstructured":"Riggs AD (1975) X inactivation, differentiation, and DNA methylation. Cytogenet Cell Genet 14:9\u201325","journal-title":"Cytogenet Cell Genet"},{"key":"2857_CR67","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0092-8674(00)81887-5","volume":"88","author":"X Nan","year":"1997","unstructured":"Nan X, Campoy FJ, Bird A (1997) MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88:471\u2013481","journal-title":"Cell"},{"key":"2857_CR68","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrg3230","volume":"13","author":"PA Jones","year":"2012","unstructured":"Jones PA (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13:484\u2013492","journal-title":"Nat Rev Genet"},{"key":"2857_CR69","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1126\/science.1170116","volume":"324","author":"M Tahiliani","year":"2009","unstructured":"Tahiliani M et al (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930\u2013935","journal-title":"Science"},{"key":"2857_CR70","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.1169786","volume":"324","author":"S Kriaucionis","year":"2009","unstructured":"Kriaucionis S, Heintz N (2009) The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324:929\u2013930","journal-title":"Science"},{"key":"2857_CR71","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/ncomms2995","volume":"4","author":"H Gan","year":"2013","unstructured":"Gan H et al (2013) Dynamics of 5-hydroxymethylcytosine during mouse spermatogenesis. Nat Commun 4:1995","journal-title":"Nat Commun"},{"key":"2857_CR72","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1053\/j.seminhematol.2013.01.004","volume":"50","author":"J Madzo","year":"2013","unstructured":"Madzo J, Vasanthakumar A, Godley LA (2013) Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies. Semin Hematol 50:61\u201369","journal-title":"Semin Hematol"},{"key":"2857_CR73","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/nn.2959","volume":"14","author":"KE Szulwach","year":"2011","unstructured":"Szulwach KE et al (2011) 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci 14:1607\u20131616","journal-title":"Nat Neurosci"},{"key":"2857_CR74","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrg2540","volume":"10","author":"H Cedar","year":"2009","unstructured":"Cedar H, Bergman Y (2009) Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 10:295\u2013304","journal-title":"Nat Rev Genet"},{"key":"2857_CR75","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2217\/epi.10.44","volume":"2","author":"H Hashimoto","year":"2010","unstructured":"Hashimoto H, Vertino PM, Cheng X (2010) Molecular coupling of DNA methylation and histone methylation. Epigenomics 2:657\u2013669","journal-title":"Epigenomics"},{"key":"2857_CR76","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0092-8674(02)00964-9","volume":"111","author":"JR Wilson","year":"2002","unstructured":"Wilson JR, Jing C, Walker PA, Martin SR, Howell SA, Blackburn GM, Gamblin SJ, Xiao B (2002) Crystal structure and functional analysis of the histone methyltransferase SET7\/9. Cell 111:105\u2013115","journal-title":"Cell"},{"key":"2857_CR77","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4161\/epi.24234","volume":"8","author":"ST Keating","year":"2013","unstructured":"Keating ST, El-Osta A (2013) Transcriptional regulation by the Set7 lysine methyltransferase. Epigenetics 8:361\u2013372","journal-title":"Epigenetics"},{"key":"2857_CR78","doi-asserted-by":"publisher","first-page":"383","DOI":"10.4161\/epi.4.6.9450","volume":"4","author":"S Pradhan","year":"2009","unstructured":"Pradhan S, Chin HG, Esteve PO, Jacobsen SE (2009) SET7\/9 mediated methylation of non-histone proteins in mammalian cells. Epigenetics 4:383\u2013387","journal-title":"Epigenetics"},{"key":"2857_CR79","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1073\/pnas.0810362106","volume":"106","author":"PO Esteve","year":"2009","unstructured":"Esteve PO, Chin HG, Benner J, Feehery GR, Samaranayake M, Horwitz GA, Jacobsen SE, Pradhan S (2009) Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells. Proc Natl Acad Sci USA 106:5076\u20135081","journal-title":"Proc Natl Acad Sci USA"},{"key":"2857_CR80","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbrc.2009.01.185","volume":"381","author":"T Masatsugu","year":"2009","unstructured":"Masatsugu T, Yamamoto K (2009) Multiple lysine methylation of PCAF by Set9 methyltransferase. Biochem Biophys Res Commun 381:22\u201326","journal-title":"Biochem Biophys Res Commun"},{"key":"2857_CR81","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1038\/sj.onc.1210599","volume":"26","author":"XJ Yang","year":"2007","unstructured":"Yang XJ, Seto E (2007) HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26:5310\u20135318","journal-title":"Oncogene"},{"key":"2857_CR82","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/20974","volume":"399","author":"C Dhalluin","year":"1999","unstructured":"Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM (1999) Structure and ligand of a histone acetyltransferase bromodomain. Nature 399:491\u2013496","journal-title":"Nature"},{"key":"2857_CR83","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.molmed.2007.07.003","volume":"13","author":"GG Wang","year":"2007","unstructured":"Wang GG, Allis CD, Chi P (2007) Chromatin remodeling and cancer, part I: covalent histone modifications. Trends Mol Med 13:363\u2013372","journal-title":"Trends Mol Med"},{"key":"2857_CR84","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1126\/science.1175371","volume":"325","author":"C Choudhary","year":"2009","unstructured":"Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325:834\u2013840","journal-title":"Science"},{"key":"2857_CR85","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1042\/CS20160084","volume":"130","author":"SN Batchu","year":"2016","unstructured":"Batchu SN, Brijmohan AS, Advani A (2016) The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease. Clin Sci (Lond) 130:987\u20131003","journal-title":"Clin Sci (Lond)"},{"key":"2857_CR86","doi-asserted-by":"publisher","first-page":"8467","DOI":"10.1128\/MCB.24.19.8467-8476.2004","volume":"24","author":"S Chang","year":"2004","unstructured":"Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24:8467\u20138476","journal-title":"Mol Cell Biol"},{"key":"2857_CR87","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0968-0004(01)02031-X","volume":"27","author":"TA McKinsey","year":"2002","unstructured":"McKinsey TA, Zhang CL, Olson EN (2002) MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci 27:40\u201347","journal-title":"Trends Biochem Sci"},{"key":"2857_CR88","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1101\/gad.11.8.1048","volume":"11","author":"CT Kuo","year":"1997","unstructured":"Kuo CT, Morrisey EE, Anandappa R, Sigrist K, Lu MM, Parmacek MS, Soudais C, Leiden JM (1997) GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev 11:1048\u20131060","journal-title":"Genes Dev"},{"key":"2857_CR89","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1101\/gad.11.8.1061","volume":"11","author":"JD Molkentin","year":"1997","unstructured":"Molkentin JD, Lin Q, Duncan SA, Olson EN (1997) Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev 11:1061\u20131072","journal-title":"Genes Dev"},{"key":"2857_CR90","doi-asserted-by":"publisher","first-page":"14471","DOI":"10.1073\/pnas.0602543103","volume":"103","author":"E Bisping","year":"2006","unstructured":"Bisping E et al (2006) Gata4 is required for maintenance of postnatal cardiac function and protection from pressure overload-induced heart failure. Proc Natl Acad Sci USA 103:14471\u201314476","journal-title":"Proc Natl Acad Sci USA"},{"key":"2857_CR91","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1038\/ncomms5907","volume":"5","author":"A He","year":"2014","unstructured":"He A et al (2014) Dynamic GATA4 enhancers shape the chromatin landscape central to heart development and disease. Nat Commun 5:4907","journal-title":"Nat Commun"},{"key":"2857_CR92","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/cvr\/cvr109","volume":"90","author":"MP Turunen","year":"2011","unstructured":"Turunen MP, Yla-Herttuala S (2011) Epigenetic regulation of key vascular genes and growth factors. Cardiovasc Res 90:441\u2013446","journal-title":"Cardiovasc Res"},{"key":"2857_CR93","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/35020506","volume":"406","author":"S Rea","year":"2000","unstructured":"Rea S et al (2000) Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406:593\u2013599","journal-title":"Nature"},{"key":"2857_CR94","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00018-009-0010-x","volume":"66","author":"SS Wolf","year":"2009","unstructured":"Wolf SS (2009) The protein arginine methyltransferase family: an update about function, new perspectives and the physiological role in humans. Cell Mol Life Sci 66:2109\u20132121","journal-title":"Cell Mol Life Sci"},{"key":"2857_CR95","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/nature04021","volume":"437","author":"MG Lee","year":"2005","unstructured":"Lee MG, Wynder C, Cooch N, Shiekhattar R (2005) An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437:432\u2013435","journal-title":"Nature"},{"key":"2857_CR96","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature04020","volume":"437","author":"E Metzger","year":"2005","unstructured":"Metzger E et al (2005) LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437:436\u2013439","journal-title":"Nature"},{"key":"2857_CR97","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","volume":"119","author":"Y Shi","year":"2004","unstructured":"Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:941\u2013953","journal-title":"Cell"},{"key":"2857_CR98","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nature04433","volume":"439","author":"Y Tsukada","year":"2006","unstructured":"Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P, Zhang Y (2006) Histone demethylation by a family of JmjC domain-containing proteins. Nature 439:811\u2013816","journal-title":"Nature"},{"key":"2857_CR99","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1126\/science.1145801","volume":"318","author":"B Chang","year":"2007","unstructured":"Chang B, Chen Y, Zhao Y, Bruick RK (2007) JMJD6 is a histone arginine demethylase. Science 318:444\u2013447","journal-title":"Science"},{"key":"2857_CR100","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2007.05.009","volume":"129","author":"A Barski","year":"2007","unstructured":"Barski A et al (2007) High-resolution profiling of histone methylations in the human genome. Cell 129:823\u2013837","journal-title":"Cell"},{"key":"2857_CR101","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/ng1966","volume":"39","author":"ND Heintzman","year":"2007","unstructured":"Heintzman ND et al (2007) Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 39:311\u2013318","journal-title":"Nat Genet"},{"key":"2857_CR102","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1365-2443.2008.01252.x","volume":"14","author":"R Kaneda","year":"2009","unstructured":"Kaneda R et al (2009) Genome-wide histone methylation profile for heart failure. Genes Cells 14:69\u201377","journal-title":"Genes Cells"},{"key":"2857_CR103","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.devcel.2007.09.004","volume":"13","author":"SR Patel","year":"2007","unstructured":"Patel SR, Kim D, Levitan I, Dressler GR (2007) The BRCT-domain containing protein PTIP links PAX2 to a histone H3, lysine 4 methyltransferase complex. Dev Cell 13:580\u2013592","journal-title":"Dev Cell"},{"key":"2857_CR104","doi-asserted-by":"publisher","first-page":"e0127839","DOI":"10.1371\/journal.pone.0127839","volume":"10","author":"AB Stein","year":"2015","unstructured":"Stein AB, Goonewardena SN, Jones TA, Prusick PJ, Bazzi AA, Belyavskaya JM, McCoskey MM, Dandar RA (2015) The PTIP-associated histone methyltransferase complex prevents stress-induced maladaptive cardiac remodeling. PLoS One 10:e0127839","journal-title":"PLoS One"},{"key":"2857_CR105","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1172\/JCI46277","volume":"121","author":"QJ Zhang","year":"2011","unstructured":"Zhang QJ, Chen HZ, Wang L, Liu DP, Hill JA, Liu ZP (2011) The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. J Clin Investig 121:2447\u20132456","journal-title":"J Clin Investig"},{"key":"2857_CR106","first-page":"319","volume":"41","author":"M Oki","year":"2007","unstructured":"Oki M, Aihara H, Ito T (2007) Role of histone phosphorylation in chromatin dynamics and its implications in diseases. Subcell Biochem 41:319\u2013336","journal-title":"Subcell Biochem"},{"key":"2857_CR107","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1073\/pnas.0813013106","volume":"106","author":"J Backs","year":"2009","unstructured":"Backs J et al (2009) The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci USA 106:2342\u20132347","journal-title":"Proc Natl Acad Sci USA"},{"key":"2857_CR108","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/path.4489","volume":"235","author":"S Awad","year":"2015","unstructured":"Awad S et al (2015) Control of histone H3 phosphorylation by CaMKIIdelta in response to haemodynamic cardiac stress. J Pathol 235:606\u2013618","journal-title":"J Pathol"},{"key":"2857_CR109","doi-asserted-by":"publisher","first-page":"7656","DOI":"10.1093\/nar\/gkt500","volume":"41","author":"S Awad","year":"2013","unstructured":"Awad S, Kunhi M, Little GH, Bai Y, An W, Bers D, Kedes L, Poizat C (2013) Nuclear CaMKII enhances histone H3 phosphorylation and remodels chromatin during cardiac hypertrophy. Nucleic Acids Res 41:7656\u20137672","journal-title":"Nucleic Acids Res"},{"key":"2857_CR110","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nature02985","volume":"431","author":"H Wang","year":"2004","unstructured":"Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, Zhang Y (2004) Role of histone H2A ubiquitination in Polycomb silencing. Nature 431:873\u2013878","journal-title":"Nature"},{"key":"2857_CR111","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1101\/gad.1404206","volume":"20","author":"D Nathan","year":"2006","unstructured":"Nathan D et al (2006) Histone sumoylation is a negative regulator in Saccharomyces cerevisiae and shows dynamic interplay with positive-acting histone modifications. Genes Dev 20:966\u2013976","journal-title":"Genes Dev"},{"key":"2857_CR112","doi-asserted-by":"publisher","first-page":"19915","DOI":"10.1073\/pnas.1009023107","volume":"107","author":"K Sakabe","year":"2010","unstructured":"Sakabe K, Wang Z, Hart GW (2010) \u03b2-N-acetylglucosamine (O-GlcNAc) is part of the histone code. Proc Natl Acad Sci 107:19915\u201319920","journal-title":"Proc Natl Acad Sci"},{"key":"2857_CR113","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.tcb.2011.06.001","volume":"21","author":"S Messner","year":"2011","unstructured":"Messner S, Hottiger MO (2011) Histone ADP-ribosylation in DNA repair, replication and transcription. Trends Cell Biol 21:534\u2013542","journal-title":"Trends Cell Biol"},{"key":"2857_CR114","doi-asserted-by":"publisher","first-page":"20164","DOI":"10.1073\/pnas.1315155110","volume":"110","author":"R Papait","year":"2013","unstructured":"Papait R et al (2013) Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. Proc Natl Acad Sci USA 110:20164\u201320169","journal-title":"Proc Natl Acad Sci USA"},{"key":"2857_CR115","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41467-017-02762-z","volume":"9","author":"R Gilsbach","year":"2018","unstructured":"Gilsbach R et al (2018) Distinct epigenetic programs regulate cardiac myocyte development and disease in the human heart in vivo. Nat Commun 9:391","journal-title":"Nat Commun"},{"key":"2857_CR116","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2353\/ajpath.2010.090528","volume":"176","author":"AB Gaikwad","year":"2010","unstructured":"Gaikwad AB, Sayyed SG, Lichtnekert J, Tikoo K, Anders HJ (2010) Renal failure increases cardiac histone h3 acetylation, dimethylation, and phosphorylation and the induction of cardiomyopathy-related genes in type 2 diabetes. Am J Pathol 176:1079\u20131083","journal-title":"Am J Pathol"},{"key":"2857_CR117","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1016\/j.yexcr.2010.07.004","volume":"316","author":"XY Yu","year":"2010","unstructured":"Yu XY, Geng YJ, Liang JL, Lin QX, Lin SG, Zhang S, Li Y (2010) High levels of glucose induce apoptosis in cardiomyocyte via epigenetic regulation of the insulin-like growth factor receptor. Exp Cell Res 316:2903\u20132909","journal-title":"Exp Cell Res"},{"key":"2857_CR118","doi-asserted-by":"publisher","first-page":"8891","DOI":"10.1007\/s11033-012-1756-z","volume":"39","author":"XY Yu","year":"2012","unstructured":"Yu XY et al (2012) High levels of glucose induce \u201cmetabolic memory\u201d in cardiomyocyte via epigenetic histone H3 lysine 9 methylation. Mol Biol Rep 39:8891\u20138898","journal-title":"Mol Biol Rep"},{"key":"2857_CR119","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jnutbio.2015.06.006","volume":"26","author":"PK Bagul","year":"2015","unstructured":"Bagul PK, Deepthi N, Sultana R, Banerjee SK (2015) Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NFkB-p65 and histone 3. J Nutr Biochem 26:1298\u20131307","journal-title":"J Nutr Biochem"},{"key":"2857_CR120","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1042\/CS20170064","volume":"131","author":"Z Xu","year":"2017","unstructured":"Xu Z et al (2017) Inhibition of HDAC3 prevents diabetic cardiomyopathy in OVE26 mice via epigenetic regulation of DUSP5-ERK1\/2 pathway. Clin Sci (Lond) 131:1841\u20131857","journal-title":"Clin Sci (Lond)"},{"key":"2857_CR121","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1475-2840-13-89","volume":"13","author":"A Bugyei-Twum","year":"2014","unstructured":"Bugyei-Twum A, Advani A, Advani SL, Zhang Y, Thai K, Kelly DJ, Connelly KA (2014) High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. Cardiovasc Diabetol 13:89","journal-title":"Cardiovasc Diabetol"},{"key":"2857_CR122","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.2337\/db06-0519","volume":"55","author":"H Kaur","year":"2006","unstructured":"Kaur H, Chen S, Xin X, Chiu J, Khan ZA, Chakrabarti S (2006) Diabetes-induced extracellular matrix protein expression is mediated by transcription coactivator p300. Diabetes 55:3104\u20133111","journal-title":"Diabetes"},{"key":"2857_CR123","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1002\/jcb.25902","volume":"118","author":"L Zhang","year":"2017","unstructured":"Zhang L et al (2017) Sodium butyrate protects-against high fat diet-induced cardiac dysfunction and metabolic disorders in type II diabetic mice. J Cell Biochem 118:2395\u20132408","journal-title":"J Cell Biochem"},{"key":"2857_CR124","doi-asserted-by":"publisher","first-page":"e65474","DOI":"10.1371\/journal.pone.0065474","volume":"8","author":"TC Zhao","year":"2013","unstructured":"Zhao TC, Du J, Zhuang S, Liu P, Zhang LX (2013) HDAC inhibition elicits myocardial protective effect through modulation of MKK3\/Akt-1. PLoS One 8:e65474","journal-title":"PLoS One"},{"key":"2857_CR125","doi-asserted-by":"publisher","first-page":"H833","DOI":"10.1152\/ajpheart.00418.2009","volume":"298","author":"M Sulaiman","year":"2010","unstructured":"Sulaiman M, Matta MJ, Sunderesan NR, Gupta MP, Periasamy M, Gupta M (2010) Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 298:H833\u2013H843","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2857_CR126","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1681\/ASN.2010060633","volume":"21","author":"G Sun","year":"2010","unstructured":"Sun G, Reddy MA, Yuan H, Lanting L, Kato M, Natarajan R (2010) Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol 21:2069\u20132080","journal-title":"J Am Soc Nephrol"},{"key":"2857_CR127","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.2337\/db13-0731","volume":"63","author":"M Vecellio","year":"2014","unstructured":"Vecellio M et al (2014) The histone acetylase activator pentadecylidenemalonate 1b rescues proliferation and differentiation in the human cardiac mesenchymal cells of type 2 diabetic patients. Diabetes 63:2132\u20132147","journal-title":"Diabetes"},{"key":"2857_CR128","doi-asserted-by":"publisher","first-page":"7480","DOI":"10.1073\/pnas.95.13.7480","volume":"95","author":"Y Wei","year":"1998","unstructured":"Wei Y, Mizzen CA, Cook RG, Gorovsky MA, Allis CD (1998) Phosphorylation of histone H3 at serine 10 is correlated with chromosome condensation during mitosis and meiosis in Tetrahymena. Proc Natl Acad Sci USA 95:7480\u20137484","journal-title":"Proc Natl Acad Sci USA"},{"key":"2857_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1432-1033.1978.tb12135.x","volume":"84","author":"LR Gurley","year":"1978","unstructured":"Gurley LR, D\u2019Anna JA, Barham SS, Deaven LL, Tobey RA (1978) Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem 84:1\u201315","journal-title":"Eur J Biochem"},{"key":"2857_CR130","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/cvr\/cvx100","volume":"113","author":"D Abdurrachim","year":"2017","unstructured":"Abdurrachim D et al (2017) Diabetic db\/db mice do not develop heart failure upon pressure overload: a longitudinal in vivo PET, MRI, and MRS study on cardiac metabolic, structural, and functional adaptations. Cardiovasc Res 113:1148\u20131160","journal-title":"Cardiovasc Res"},{"key":"2857_CR131","doi-asserted-by":"publisher","first-page":"e92903","DOI":"10.1371\/journal.pone.0092903","volume":"9","author":"EJ Cox","year":"2014","unstructured":"Cox EJ, Marsh SA (2014) A systematic review of fetal genes as biomarkers of cardiac hypertrophy in rodent models of diabetes. PLoS One 9:e92903","journal-title":"PLoS One"},{"key":"2857_CR132","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.728550","volume":"117","author":"L Heerebeek van","year":"2008","unstructured":"van Heerebeek L et al (2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117:43\u201351","journal-title":"Circulation"},{"key":"2857_CR133","first-page":"7242384","volume":"2017","author":"J Sun","year":"2017","unstructured":"Sun J, Wang Y, Cui W, Lou Y, Sun G, Zhang D, Miao L (2017) Role of epigenetic histone modifications in diabetic kidney disease involving renal fibrosis. J Diabetes Res 2017:7242384","journal-title":"J Diabetes Res"},{"key":"2857_CR134","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1161\/CIRCRESAHA.110.223172","volume":"107","author":"EM Small","year":"2010","unstructured":"Small EM et al (2010) Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ Res 107:294\u2013304","journal-title":"Circ Res"},{"key":"2857_CR135","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1681\/ASN.2014070678","volume":"26","author":"H Xu","year":"2015","unstructured":"Xu H, Wu X, Qin H, Tian W, Chen J, Sun L, Fang M, Xu Y (2015) Myocardin-related transcription factor A epigenetically regulates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol 26:1648\u20131660","journal-title":"J Am Soc Nephrol"},{"issue":"911\u201316","key":"2857_CR136","first-page":"e12","volume":"110","author":"J Uribarri","year":"2010","unstructured":"Uribarri J et al (2010) Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 110(911\u201316):e12","journal-title":"J Am Diet Assoc"},{"key":"2857_CR137","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.2337\/dc15-0925","volume":"38","author":"MC Thomas","year":"2015","unstructured":"Thomas MC et al (2015) Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes. Diabetes Care 38:1891\u20131897","journal-title":"Diabetes Care"},{"key":"2857_CR138","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.freeradbiomed.2011.01.034","volume":"50","author":"S Pashikanti","year":"2011","unstructured":"Pashikanti S, Boissonneault GA, Cervantes-Laurean D (2011) Ex vivo detection of histone H1 modified with advanced glycation end products. Free Radic Biol Med 50:1410\u20131416","journal-title":"Free Radic Biol Med"},{"key":"2857_CR139","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1006\/bbrc.1995.1935","volume":"212","author":"A Gugliucci","year":"1995","unstructured":"Gugliucci A, Bendayan M (1995) Histones from diabetic rats contain increased levels of advanced glycation end products. Biochem Biophys Res Commun 212:56\u201362","journal-title":"Biochem Biophys Res Commun"},{"key":"2857_CR140","doi-asserted-by":"publisher","first-page":"26771","DOI":"10.1074\/jbc.M802800200","volume":"283","author":"Y Li","year":"2008","unstructured":"Li Y, Reddy MA, Miao F, Shanmugam N, Yee JK, Hawkins D, Ren B, Natarajan R (2008) Role of the histone H3 lysine 4 methyltransferase, SET7\/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem 283:26771\u201326781","journal-title":"J Biol Chem"},{"key":"2857_CR141","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1084\/jem.20081188","volume":"205","author":"A El-Osta","year":"2008","unstructured":"El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M (2008) Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 205:2409\u20132417","journal-title":"J Exp Med"},{"key":"2857_CR142","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2337\/db10-0133","volume":"60","author":"Q Zhong","year":"2011","unstructured":"Zhong Q, Kowluru RA (2011) Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes 60:1304\u20131313","journal-title":"Diabetes"},{"key":"2857_CR143","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1681\/ASN.2008020142","volume":"20","author":"A Advani","year":"2009","unstructured":"Advani A et al (2009) Expression, localization, and function of the thioredoxin system in diabetic nephropathy. J Am Soc Nephrol 20:730\u2013741","journal-title":"J Am Soc Nephrol"},{"key":"2857_CR144","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00592-014-0608-9","volume":"51","author":"KA Connelly","year":"2014","unstructured":"Connelly KA et al (2014) Impaired cardiac anti-oxidant activity in diabetes: human and correlative experimental studies. Acta Diabetol 51:771\u2013782","journal-title":"Acta Diabetol"},{"key":"2857_CR145","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1681\/ASN.2014090898","volume":"27","author":"FS Siddiqi","year":"2016","unstructured":"Siddiqi FS et al (2016) The histone methyltransferase enzyme enhancer of Zeste homolog 2 protects against podocyte oxidative stress and renal injury in diabetes. J Am Soc Nephrol 27:2021\u20132034","journal-title":"J Am Soc Nephrol"},{"key":"2857_CR146","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jcp.21852","volume":"221","author":"L Perrone","year":"2009","unstructured":"Perrone L, Devi TS, Hosoya K, Terasaki T, Singh LP (2009) Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol 221:262\u2013272","journal-title":"J Cell Physiol"},{"key":"2857_CR147","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1161\/CIRCRESAHA.111.243592","volume":"109","author":"S Zhou","year":"2011","unstructured":"Zhou S et al (2011) Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction. Circ Res 109:639\u2013648","journal-title":"Circ Res"},{"key":"2857_CR148","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.2337\/db17-0294","volume":"66","author":"S Costantino","year":"2017","unstructured":"Costantino S et al (2017) Impact of glycemic variability on chromatin remodeling, oxidative stress, and endothelial dysfunction in patients with type 2 diabetes and with target HbA1c levels. Diabetes 66:2472\u20132482","journal-title":"Diabetes"},{"key":"2857_CR149","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41467-017-00498-4","volume":"8","author":"M Liu","year":"2017","unstructured":"Liu M et al (2017) Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling. Nat Commun 8:413","journal-title":"Nat Commun"},{"key":"2857_CR150","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.2337\/db14-0872","volume":"64","author":"KA Gallagher","year":"2015","unstructured":"Gallagher KA et al (2015) Epigenetic changes in bone marrow progenitor cells influence the inflammatory phenotype and alter wound healing in type 2 diabetes. Diabetes 64:1420\u20131430","journal-title":"Diabetes"},{"key":"2857_CR151","doi-asserted-by":"publisher","first-page":"9047","DOI":"10.1073\/pnas.0803623105","volume":"105","author":"LM Villeneuve","year":"2008","unstructured":"Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R (2008) Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA 105:9047\u20139052","journal-title":"Proc Natl Acad Sci USA"},{"key":"2857_CR152","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MCO.0000000000000375","volume":"20","author":"S Sharma","year":"2017","unstructured":"Sharma S, Kriebel J, Grallert H (2017) Epigenetic regulation of glucose metabolism. Curr Opin Clin Nutr Metab Care 20:266\u2013271","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2857_CR153","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.bbadis.2016.07.020","volume":"1862","author":"A Fukushima","year":"2016","unstructured":"Fukushima A, Lopaschuk GD (2016) Acetylation control of cardiac fatty acid beta-oxidation and energy metabolism in obesity, diabetes, and heart failure. Biochim Biophys Acta 1862:2211\u20132220","journal-title":"Biochim Biophys Acta"},{"key":"2857_CR154","first-page":"1","volume":"2","author":"EM Taylor","year":"2014","unstructured":"Taylor EM, Jones AD, Henagan TM (2014) A review of mitochondrial-derived fatty acids in epigenetic regulation of obesity and type 2 diabetes. J Nutr Health Food Sci 2:1\u20134","journal-title":"J Nutr Health Food Sci"},{"key":"2857_CR155","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.2337\/db12-1141","volume":"62","author":"Q Zhong","year":"2013","unstructured":"Zhong Q, Kowluru RA (2013) Regulation of matrix metalloproteinase-9 by epigenetic modifications and the development of diabetic retinopathy. Diabetes 62:2559\u20132568","journal-title":"Diabetes"},{"key":"2857_CR156","doi-asserted-by":"publisher","first-page":"10783","DOI":"10.1073\/pnas.0914507107","volume":"107","author":"PJ Rugg-Gunn","year":"2010","unstructured":"Rugg-Gunn PJ, Cox BJ, Ralston A, Rossant J (2010) Distinct histone modifications in stem cell lines and tissue lineages from the early mouse embryo. Proc Natl Acad Sci USA 107:10783\u201310790","journal-title":"Proc Natl Acad Sci USA"},{"key":"2857_CR157","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1172\/JCI95946","volume":"128","author":"S Majumder","year":"2018","unstructured":"Majumder S et al (2018) Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease. J Clin Investig 128:483\u2013499","journal-title":"J Clin Investig"},{"key":"2857_CR158","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00280-013-2220-z","volume":"72","author":"M Iwamoto","year":"2013","unstructured":"Iwamoto M, Friedman EJ, Sandhu P, Agrawal NG, Rubin EH, Wagner JA (2013) Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol 72:493\u2013508","journal-title":"Cancer Chemother Pharmacol"},{"key":"2857_CR159","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.canlet.2009.01.002","volume":"280","author":"VM Richon","year":"2009","unstructured":"Richon VM, Garcia-Vargas J, Hardwick JS (2009) Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280:201\u2013210","journal-title":"Cancer Lett"},{"key":"2857_CR160","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1021\/jm800251w","volume":"51","author":"N Zhou","year":"2008","unstructured":"Zhou N et al (2008) Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem 51:4072\u20134075","journal-title":"J Med Chem"},{"key":"2857_CR161","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1042\/BJ20070779","volume":"409","author":"N Khan","year":"2008","unstructured":"Khan N et al (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409:581\u2013589","journal-title":"Biochem J"},{"key":"2857_CR162","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1007\/s10495-017-1410-2","volume":"22","author":"VR Pidugu","year":"2017","unstructured":"Pidugu VR, Yarla NS, Bishayee A, Kalle AM, Satya AK (2017) Novel histone deacetylase 8-selective inhibitor 1,3,4-oxadiazole-alanine hybrid induces apoptosis in breast cancer cells. Apoptosis 22:1394\u20131403","journal-title":"Apoptosis"},{"key":"2857_CR163","doi-asserted-by":"publisher","first-page":"7984","DOI":"10.1021\/acs.jmedchem.7b00462","volume":"60","author":"DP Mould","year":"2017","unstructured":"Mould DP et al (2017) Development of (4-cyanophenyl)glycine derivatives as reversible inhibitors of lysine specific demethylase 1. J Med Chem 60:7984\u20137999","journal-title":"J Med Chem"},{"key":"2857_CR164","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1016\/j.bmcl.2017.08.052","volume":"27","author":"DP Mould","year":"2017","unstructured":"Mould DP, Bremberg U, Jordan AM, Geitmann M, McGonagle AE, Somervaille TCP, Spencer GJ, Ogilvie DJ (2017) Development and evaluation of 4-(pyrrolidin-3-yl)benzonitrile derivatives as inhibitors of lysine specific demethylase 1. Bioorg Med Chem Lett 27:4755\u20134759","journal-title":"Bioorg Med Chem Lett"},{"key":"2857_CR165","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nature11262","volume":"488","author":"L Kruidenier","year":"2012","unstructured":"Kruidenier L et al (2012) A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488:404\u2013408","journal-title":"Nature"},{"key":"2857_CR166","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1128\/MMBR.64.2.435-459.2000","volume":"64","author":"DE Sterner","year":"2000","unstructured":"Sterner DE, Berger SL (2000) Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 64:435\u2013459","journal-title":"Microbiol Mol Biol Rev"},{"key":"2857_CR167","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev.biochem.70.1.81","volume":"70","author":"SY Roth","year":"2001","unstructured":"Roth SY, Denu JM, Allis CD (2001) Histone acetyltransferases. Annu Rev Biochem 70:81\u2013120","journal-title":"Annu Rev Biochem"},{"key":"2857_CR168","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto E, Yoshida M (2014) Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol 6:a018713","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2857_CR169","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1038\/emm.2017.11","volume":"49","author":"K Hyun","year":"2017","unstructured":"Hyun K, Jeon J, Park K, Kim J (2017) Writing, erasing and reading histone lysine methylations. Exp Mol Med 49:e324","journal-title":"Exp Mol Med"},{"key":"2857_CR170","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1101\/gad.1864410","volume":"24","author":"Y Tsukada","year":"2010","unstructured":"Tsukada Y, Ishitani T, Nakayama KI (2010) KDM7 is a dual demethylase for histone H3 Lys 9 and Lys 27 and functions in brain development. Genes Dev 24:432\u2013437","journal-title":"Genes Dev"},{"key":"2857_CR171","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrg3173","volume":"13","author":"EL Greer","year":"2012","unstructured":"Greer EL, Shi Y (2012) Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 13:343\u2013357","journal-title":"Nat Rev Genet"},{"key":"2857_CR172","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.athoracsur.2017.04.046","volume":"104","author":"E Ito","year":"2017","unstructured":"Ito E et al (2017) Histone modification is correlated with reverse left ventricular remodeling in nonischemic dilated cardiomyopathy. Ann Thorac Surg 104:1531\u20131539","journal-title":"Ann Thorac Surg"},{"key":"2857_CR173","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1161\/CIRCULATIONAHA.117.028561","volume":"136","author":"R Papait","year":"2017","unstructured":"Papait R et al (2017) Histone methyltransferase G9a is required for cardiomyocyte homeostasis and hypertrophy. Circulation 136:1233\u20131246","journal-title":"Circulation"},{"key":"2857_CR174","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.bbamcr.2016.03.002","volume":"1863","author":"P Han","year":"2016","unstructured":"Han P et al (2016) Epigenetic response to environmental stress: assembly of BRG1-G9a\/GLP-DNMT3 repressive chromatin complex on Myh6 promoter in pathologically stressed hearts. Biochim Biophys Acta 1863:1772\u20131781","journal-title":"Biochim Biophys Acta"},{"key":"2857_CR175","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.5966\/sctm.2014-0290","volume":"4","author":"L Zakharova","year":"2015","unstructured":"Zakharova L, Nural-Guvener H, Feehery L, Popovic-Sljukic S, Gaballa MA (2015) Transplantation of epigenetically modified adult cardiac c-kit+ cells retards remodeling and improves cardiac function in ischemic heart failure model. Stem Cells Transl Med 4:1086\u20131096","journal-title":"Stem Cells Transl Med"},{"key":"2857_CR176","doi-asserted-by":"publisher","first-page":"39752","DOI":"10.1038\/srep39752","volume":"7","author":"T Ono","year":"2017","unstructured":"Ono T et al (2017) The histone 3 lysine 9 methyltransferase inhibitor chaetocin improves prognosis in a rat model of high salt diet-induced heart failure. Sci Rep 7:39752","journal-title":"Sci Rep"},{"key":"2857_CR177","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1091\/mbc.e13-08-0444","volume":"24","author":"A Pedram","year":"2013","unstructured":"Pedram A, Razandi M, Narayanan R, Dalton JT, McKinsey TA, Levin ER (2013) Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Mol Biol Cell 24:3805\u20133818","journal-title":"Mol Biol Cell"},{"key":"2857_CR178","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1039\/C6MB00692B","volume":"13","author":"C Peng","year":"2017","unstructured":"Peng C, Luo X, Li S, Sun H (2017) Phenylephrine-induced cardiac hypertrophy is attenuated by a histone acetylase inhibitor anacardic acid in mice. Mol BioSyst 13:714\u2013724","journal-title":"Mol BioSyst"},{"key":"2857_CR179","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1172\/JCI88353","volume":"127","author":"B Thienpont","year":"2017","unstructured":"Thienpont B et al (2017) The H3K9 dimethyltransferases EHMT1\/2 protect against pathological cardiac hypertrophy. J Clin Investig 127:335\u2013348","journal-title":"J Clin Investig"},{"key":"2857_CR180","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.toxlet.2017.08.011","volume":"280","author":"LF Pharaon","year":"2017","unstructured":"Pharaon LF, El-Orabi NF, Kunhi M, Al Yacoub N, Awad SM, Poizat C (2017) Rosiglitazone promotes cardiac hypertrophy and alters chromatin remodeling in isolated cardiomyocytes. Toxicol Lett 280:151\u2013158","journal-title":"Toxicol Lett"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00018-018-2857-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-018-2857-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-018-2857-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T19:39:41Z","timestamp":1569181181000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00018-018-2857-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,22]]},"references-count":180,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["2857"],"URL":"https:\/\/doi.org\/10.1007\/s00018-018-2857-1","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,22]]},"assertion":[{"value":"19 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AA has received research support through his institution from Boehringer Ingelheim and AstraZeneca, and is listed as an inventor on a patent application filed by Boehringer Ingelheim on the treatment of heart failure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}